Arrowhead Pharmaceuticals (ARWR) Common Equity (2016 - 2025)
Historic Common Equity for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $568.4 million.
- Arrowhead Pharmaceuticals' Common Equity rose 91368.17% to $568.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $568.4 million, marking a year-over-year increase of 91368.17%. This contributed to the annual value of $503.4 million for FY2025, which is 16348.17% up from last year.
- According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' Common Equity is $568.4 million, which was up 91368.17% from $503.4 million recorded in Q3 2025.
- Arrowhead Pharmaceuticals' Common Equity's 5-year high stood at $684.2 million during Q1 2025, with a 5-year trough of $56.1 million in Q4 2024.
- In the last 5 years, Arrowhead Pharmaceuticals' Common Equity had a median value of $427.6 million in 2021 and averaged $403.6 million.
- In the last 5 years, Arrowhead Pharmaceuticals' Common Equity crashed by 6771.99% in 2024 and then surged by 91368.17% in 2025.
- Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Common Equity stood at $372.6 million in 2021, then increased by 6.39% to $396.4 million in 2022, then plummeted by 56.17% to $173.7 million in 2023, then plummeted by 67.72% to $56.1 million in 2024, then soared by 913.68% to $568.4 million in 2025.
- Its last three reported values are $568.4 million in Q4 2025, $503.4 million for Q3 2025, and $522.3 million during Q2 2025.